Affordable Access

deepdyve-link
Publisher Website

Neutralising antibody escape of SARS-CoV-2 spike protein: Risk assessment for antibody-based Covid-19 therapeutics and vaccines.

Authors
  • Focosi, Daniele1
  • Maggi, Fabrizio2
  • 1 North-Western Tuscany Blood Bank, Pisa University Hospital, Pisa, Italy. , (Italy)
  • 2 Department of Medicine and Surgery, University of Insubria, Varese, Italy. , (Italy)
Type
Published Article
Journal
Reviews in medical virology
Publication Date
Nov 01, 2021
Volume
31
Issue
6
Identifiers
DOI: 10.1002/rmv.2231
PMID: 33724631
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

The Spike protein is the target of both antibody-based therapeutics (convalescent plasma, polyclonal serum, monoclonal antibodies) and vaccines. Mutations in Spike could affect efficacy of those treatments. Hence, monitoring of mutations is necessary to forecast and readapt the inventory of therapeutics. Different phylogenetic nomenclatures have been used for the currently circulating SARS-CoV-2 clades. The Spike protein has different hotspots of mutation and deletion, the most dangerous for immune escape being the ones within the receptor binding domain (RBD), such as K417N/T, N439K, L452R, Y453F, S477N, E484K, and N501Y. Convergent evolution has led to different combinations of mutations among different clades. In this review we focus on the main variants of concern, that is, the so-called UK (B.1.1.7), South African (B.1.351) and Brazilian (P.1) strains. © 2021 John Wiley & Sons Ltd.

Report this publication

Statistics

Seen <100 times